The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Persistent Negative Symptoms in Schizophrenia: An Overview
Open accessAbstract
Persistent negative symptoms represent an alternative approach for assessing negative symptoms in the context of clinical trials. Persistent negative symptoms are designed to capture those symptoms that lead to functional impairment but are currently understudied and for which there are no currently available effective treatments. Persistent negative symptoms differ from the 2 most commonly used approaches: primary, enduring negative symptoms or deficit symptoms and negative symptoms broadly defined to include negative symptoms, regardless of their etiology or duration. In contrast to deficit symptoms, persistent negative symptoms may include secondary negative symptoms. However, in contrast to negative symptoms broadly defined, the secondary negative symptoms included in the assessment of persistent negative symptoms only include those that have failed to respond to usual treatments for secondary negative symptoms. In consequence, the presence of persistent negative symptoms identifies a patient population with clinically relevant symptomatology, which is larger than the one with the deficit syndrome but less heterogeneous than that captured through the use of a nonrestrictive definition of negative symptoms. This may facilitate the selection of subjects for inclusion into research and efforts to develop new pharmacological treatments and enhance our understanding of a relevant clinical problem. Ultimately, the investigation of the different entities characterized by negative symptoms, such as persistent negative symptoms, and the enhanced understanding of their biological and clinical characteristics may help to unravel the psychopathological and biological heterogeneity of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,901
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Negative v Positive Schizophrenia: Definition and Validation
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,012
Cited by
Garland, E. L., Fredrickson, B., Kring, A. M., Johnson, D. P., Meyer, P. S., & Penn, D. L. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.03.002 · Cited by 1,035
“Additionally, individuals with negative symptoms have significant impairments in motivation, treatment adherence, social functioning and long-term outcome relative to others with schizophrenia (Bowie, Reichenberg, Patterson, Heaton, & Harvey, 2006b; Buchanan, 2007).”
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Negative symptoms of schizophrenia: new developments and unanswered research questions
Galderisi, S., Mucci, A., Buchanan, R. W., & Arango, C. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30050-6 · Cited by 555
Self-citationPrefrontal Cortex and Social Cognition in Mouse and Man
Bicks, L. K., Koike, H., Akbarian, S., & Morishita, H. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01805 · Cited by 500
Motor Symptoms and Schizophrenia
Walther, S., & Strik, W. (2012) · Neuropsychobiology · doi:10.1159/000339456 · Cited by 369
Németh, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmári, B., Harsányi, J., Barabássy, Á., Debelle, M., Durgam, S., Bitter, I., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30060-0 · Cited by 357
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Treatment-Resistant Schizophrenia
Elkis, H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.001 · Cited by 338
Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., & CLAMORS Study Collaborative Group (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04250yel · Cited by 271
Neurocognition: Clinical and Functional Outcomes in Schizophrenia
Lepage, M., Bodnar, M., & Bowie, C. R. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900103 · Cited by 266
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Self-citationLutgens, D., Gariepy, G., & Malla, A. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.197103 · Cited by 181
Hunter, R., & Barry, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.015 · Cited by 138
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Hill, K., & Startup, M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.056 · Cited by 97
“Furthermore, unlike positive symptoms, negative symptomatology has been found to predict poor social functioning (Sayers et al., 1996; Rocca et al., 2009; Pratt et al., 2005; Buchanan, 2007; Grant and Beck, 2009).”
BackgroundHypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis
Belvederi Murri, M., Pariante, C. M., Dazzan, P., Hepgul, N., Papadopoulos, A. S., Zunszain, P., Di Forti, M., Murray, R. M., & Mondelli, V. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.013 · Cited by 93
Blanchard, J. J., Park, S. G., Catalano, L. T., & Bennett, M. E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.019 · Cited by 82
Hasan, A., Wolff-Menzler, C., Pfeiffer, S., Falkai, P., Weidinger, E., Jobst, A., Hoell, I., Malchow, B., Yeganeh-Doost, P., Strube, W., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0618-9 · Cited by 80
Baandrup, L. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13384 · Cited by 79
Arens, E. A., Stopsack, M., Spitzer, C., Appel, K., Dudeck, M., Völzke, H., Grabe, H. J., & Barnow, S. (2013) · Journal of Personality Disorders · doi:10.1521/pedi.2013.27.2.196 · Cited by 61
“Buchanan, R. W. (2007). Persistent negative symptoms in schizophrenia: An overview.”
BackgroundRiehle, M., Böhl, M. C., Pillny, M., & Lincoln, T. M. (2020) · Clinical Psychology in Europe · doi:10.32872/cpe.v2i3.2899 · Cited by 51
“This makes it extremely difficult to select appropriate treatments for the patients with schizophrenia, who present with relative negative symptoms, which have been estimated to constitute one (Buchanan, 2007) or even two (Bobes, Arango, Garcia-Garcia, & Rejas, 2010) thirds of the total patient population.”
BackgroundTechnology to assess and support self-management in serious mental illness
Depp, C. A., Moore, R. C., Perivoliotis, D., & Granholm, E. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.2/cdepp · Cited by 48
Lysaker, P. H., Kukla, M., Dubreucq, J., Gumley, A., McLeod, H., Vohs, J. L., Buck, K. D., Minor, K. S., Luther, L., Leonhardt, B. L., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.015 · Cited by 47
Mapping autobiographical memory in schizophrenia: Clinical implications
Ricarte, J. J., Ros, L., Latorre, J. M., & Watkins, E. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.11.004 · Cited by 45
Rakitzi, S., Georgila, P., Efthimiou, K., & Mueller, D. R. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.05.039 · Cited by 20
“Negative symptoms have face validity as disease manifestations, and represent loss or diminution of normal functions (Buchanan, 2007; Kirkpatrik et al., 2006; Kirkpatrik, 2014; Velligan et al., 2014).”
Lyngstad, S. H., Gardsjord, E. S., Simonsen, C., Engen, M. J., Romm, K. L., Melle, I., & Færden, A. (2018) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.07.015 · Cited by 12
Metadata
- Authors
- Buchanan, R. W.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-15
- Volume
- 33
- Issue
- 4
- Pages
- 1013-1022
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2171111401
- Cited by
- 443
- References
- 67
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.